BioWorld

Sep. 22, 2006

Merck KGaA Buying Serono, Giving CHF16.6B Valuation

Merck KGaA agreed to acquire a controlling stake in Serono SA by purchasing the Bertarelli family's shares in the company, which represent 64.5 percent of its equity and 75.5 percent of its voting rights. (BioWorld Today) Read More

Phase II Alzheimer's Results Boost Shares Of Medivation

Alzheimer's, Like Prion Disease, 'Seeded' By Misshapen Proteins

Alexion Seeks FDA Approval For Soliris In PNH Indication

Axcan Drops ITAX In Functional Dyspepsia After Phase III Failure

Biogen Joins With Alnylam On RNAi Therapies For PML

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

HMNC raises $50M series B to prep depression drugs for phase III

BioWorld

HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...